CeriBell (NASDAQ:CBLL) Director Sells $506,500.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 25,000 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $20.26, for a total value of $506,500.00. Following the completion of the transaction, the director owned 797,652 shares in the company, valued at approximately $16,160,429.52. The trade was a 3.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

CeriBell Stock Down 4.9%

CeriBell stock traded down $1.04 during mid-day trading on Wednesday, reaching $20.18. The stock had a trading volume of 630,162 shares, compared to its average volume of 559,477. The firm has a market capitalization of $748.68 million, a PE ratio of -13.36 and a beta of 1.35. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The stock’s 50-day simple moving average is $13.98 and its 200-day simple moving average is $14.46. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. The company had revenue of $22.59 million for the quarter, compared to analysts’ expectations of $21.78 million. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%. On average, sell-side analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on CBLL shares. JPMorgan Chase & Co. reduced their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. TD Cowen cut their price target on CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Cowen reissued a “buy” rating on shares of CeriBell in a report on Tuesday. Raymond James Financial began coverage on CeriBell in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.17.

Institutional Investors Weigh In On CeriBell

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of CeriBell by 11.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after purchasing an additional 147,013 shares during the period. Yu Fan raised its position in CeriBell by 10.7% in the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after acquiring an additional 130,964 shares during the period. Novo Holdings A S boosted its stake in CeriBell by 2.3% in the second quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock valued at $16,857,000 after acquiring an additional 20,000 shares during the last quarter. TimesSquare Capital Management LLC grew its position in shares of CeriBell by 2.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company’s stock valued at $9,395,000 after acquiring an additional 20,700 shares during the period. Finally, Millennium Management LLC increased its stake in shares of CeriBell by 41.8% during the 3rd quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock worth $7,657,000 after purchasing an additional 196,299 shares during the last quarter.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.